Reddit Posts
Have been sitting on $GERN for a while (waiting on their one and only drug to finally come to market)
Finally over a billion and over 75% institutional ownership - GERN
Dealing with Fears of Loss, that leads to many lost opportunities - help needed
Dealing with Fears of Loss, that leads to many lost opportunities - help needed
💰💰💰Good morning! #premarket #watchlist 01/04 $CRKN -Crown Electrokinetics Acquires Amerigen 7(+97%), $GERN -Announces Positive Top-Line Results from IMerge Phase 3 Trial(+49%), $TENX -Announces Reverse Stock Split(+48%)
The biotech company you’ve all been waiting for! $GERN
$GERN very promising in phase 2 clinical as results published. Phase 3 underway. Get in now.
Last Week's Most Talked About Pennystocks - ATOS, CTXR,TRCH,UONE, CBD,FAMI,GERN,GTE,EVFM
Has anyone heard anything about Geron Cop. (GERN)?
Do not buy Geron Corporation stock before seeing this video!📈 (GERN Stock Analysis)
$GERN up 40% today. Is this the start of something big or should I take the money and run?
What the hell os happening to $GERN?
GERN is taking off and it’s not too late to hop on!!
Made 7 buys today… everything I went big into is down. Throw the leftover funds into GERN and it takes off - where are my crayons, I’m hungry.
GERN! You think it’s getting shorted? Good buy?
Pretty Good Stock here, Hmmmm?
Looks like GERN is moving lower where it should be for now.
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study 🚀Geron ($GERN)
Mentions
I have completed a structural and probabilistic audit of Geron Corporation (GERN). I’M GOING ALL IN AND STARTING A SQUEEZE. The entity has transitioned from a clinical-stage narrative to a commercial execution engine following the FDA approval of Rytelo (imetelstat) in mid-2024. Phase 1: The Archetype • ECONOMIC DNA: DISRUPTOR (Commercial-Stage). Geron is moving from a "Capital Sink" to a "Revenue Engine." The core driver is Imetelstat’s first-in-class telomerase inhibitor status for Low-Risk MDS. • VALUATION BRIDGE: Market sentiment is currently depressed (trailing ~12% decline month-over-month) due to a Q3 2025 revenue miss ($47.2M vs $54M expected). The Valuation Delta is wide: the market is pricing in a "linear growth" failure, while structural reality shows a 150-account expansion (1,150 total) and a 97% gross margin. • CAPITAL VELOCITY: Currently a reinvestor. The entity is aggressively burning cash for the EU launch (2026) and the IMpactMF Phase 3 trial. Phase 2: Stability Scan • PRICING RESILIENCE: PRICE MAKER. In the orphan/specialty heme-onc space, Rytelo holds significant pricing power, though it faces competition from Bristol Myers Squibb’s Reblozyl. • CAPITAL STRUCTURE AUDIT: LEAN/STABLE. Cash and equivalents sit at $420M (as of Sept 30, 2025). With a revised downward OpEx guidance ($250M-$260M), the runway extends into 2026/27, reducing immediate dilution risk. • SYSTEMIC RISK: High sensitivity to Medicare/PBM drug pricing negotiations and the "adoption lag" in community oncology centers. Phase 3: Analytic Deep-Dive • MARKET PLUMBING: • Implied Volatility (IV): 76.0 (63rd percentile). Options are pricing in higher-than-average movement. • Put-Call Ratio (PCR): 0.06. Extreme bullish skew in open interest; the market is heavily bet on a "call-side" recovery. • Gamma Walls: High concentration at the $2.00 and $3.00 strikes. Price is currently pinned in a "liquidity vacuum" below $1.50, lacking the delta-buying pressure to trigger a squeeze. • SIGNAL AUDIT: Smart money remains anchored. RA Capital and BlackRock hold significant positions (>16% combined). Recent 1/3 workforce reduction (Dec 2025) suggests a pivot toward "Efficiency over Expansion." • TIMESTAMP: Data retrieved as of Dec 30, 2025, 21:28 EST. Phase 4: Probabilistic Synthesis (Bayesian Update) • THE PRIOR: Biotech commercial transitions succeed in scaling to profitability only ~15% of the time within 24 months. • THE UPDATES: • Tier A (1.0): FDA/EMA Approval secured; Rytelo 97% gross margins (High Quality). • Tier B (0.6): Q3 2025 revenue miss; demand down 3% QoQ; workforce reduction (Mixed Quality). • Tier C (0.3): Bullish analyst price targets ($3.00+); high short interest ratio (10+ days to cover). • THE POSTERIOR: Calculated probability of outperforming the XBI (Biotech Index) over 18 months: 58%. The workforce reduction and EU launch prep act as the primary "Update" to the success probability. Final Synthesis & Output Confluence/Divergence: DIVERGENCE. The Chart/Price Action is bearish (near 52-week lows), but the Options Chain (PCR 0.06) and Institutional Holding (RA Capital) are aggressively bullish. This signals a "Value Trap" for short-term traders but a "Generational Entry" for long-term Bayesian players. 3. CONVICTION SCORE: TIER 2 (Strategic Opportunity) • The "Product" works and the "Moat" is legal/regulatory. The "Risk" is purely execution-speed. 4. DATA INTEGRITY SCORE: 9/10 • Recent Q3 filings and Dec 2025 restructuring news provide high-freshness data.
GERN: simple biotech with some promising possibilities but Rick bottom cost right now (and rightly so, utility is still speculative).
A tale as old as time. I remember my first big option loss was on $GERN last year.
Though it gets few mentions, I've spoken about CHRS. Like most things, it took a huge beating on Friday. I held. I would still encourage people to monitor it Monday, pre-market, to see what is doing. I feel many will, again, see the value and buy in at this lower price, returning it to the multiple variable that can make it rise. I also held GERN and RVPH.
I'm on on GERN and CHRS for long
I'm in on GERN and CHRS.
Sleepers could pop anytime. $GERN $OPFI $BRCC
$GERN. Wall Street analysts are generally bullish on GERN. Out of 7 analysts, the consensus rating is "Buy," with an average 12-month price target of $3.17 (implying 147% upside from current levels). Other targets range from $3.08 to $3.63, with highs up to $5.00 and lows at $1.00. Recent News and Developments Geron has shown positive momentum from its Q2 2025 earnings, where revenue surged 5,477% year-over-year to $49 million, fueled by RYTELO commercialization. The company recently appointed Harout Semerjian as President and CEO, granting him stock options as an employment inducement. Insider buying has also supported optimism. However, the stock's recent decline may reflect broader biotech sector pressures. On X (formerly Twitter), retail sentiment includes "buy the dip" signals around $1.18 and long-term bullish strategies predicting shares could reach $15–$30 in two years amid improving sales. Overall, GERN represents a high-risk, high-reward biotech play tied to its oncology pipeline success, but investors should monitor upcoming earnings and clinical trial updates closely. This is not financial advice—consult a professional for personalized guidance.
CLSK - Charles Payne talked it up. I made $1000 already. GERN - Varney and Co talked it up. Slow roll, but made waves for a major network to mention. QBTS - ran up already some but still has legs. One of the major network shows told me about it. P.S. I have made 6 digits by buying stocks off of Payne and Varney guest recommendations.
So apparently Geron Corp (GERN) basically just cured cancer. Why doesn’t anyone seem to care?
ONON calls. LULU puts. GERN buy on dip, as shorts will dump to try to scare people off. Buy SHLS on any dip before 4.45.
REAL is on the squeeze. I expect shorts have been buying on its rise. They will dump to take some profit, to drop the price, hoping to scare others into selling, and using said profit to cover, need be. Not sure that will work, but be mindful. Watching GERN to see how it looks, with consideration for buying.
ONON calls. Expecting REAL squeeze. (Shorts will take some profit, drive the price down to scare off people and get the to sell, so holding for the return rise. On the pennies, watching ANRO and GERN.
Look at $GERN. Might be starting to take pff. (Do your own DD.)
GERN and RR are my plays
Just checked out $GERN chart on “all”- way up way down for over 25yrs they’ve been relevant. Interesting
Surprisingly no. Quick small bucks on GERN, vistra and BE
Fair enough on risk. There have been plenty of biotechs that I have missed because “it already broke”. Not saying anything about GERN (especially because it has been mentioned a lot here), but biotechs tend to run more than once
I see a lot of Reddit posts about GERN about to rocket and not about what they do… any insights?
I actually bought into $GERN last night and will hold.
I was in GERN a few years ago. They were dropped from a partnership for Imetelstat, yet kept leading on like everything was going according to plan. I joined a class action and managed to get back 20% of my losses when they settled. Never again with them.
What’s up with $GERN? Tanked back in march. Today it started climbing back up. 13% and counting so far
# Buy GERON Corp. $GERN before it sky rocket. They have money for years and NO dilution
Perhaps. But I have more faith with shorts on GERN, DD, and LMND. And a little faith shorting RKLB and JOBY simply because they're both burdened with crazy expectations and due for a huge pullback. There's already a major correction forming with the eVTOL names in particular.
RKLB - going around $100 by EOY but gotta play invest, not gamble. If gamble? IOVA or GERN, but gamble is gamble......... go long, you'll like yourself better down the road
I totally agree with you brother. These companies like GERN should get way more attention.
GERN ALBA LXRX trust
“GERN’s sales growth increased Q4’24 net product revenue by 68% to $47.5M from Q3’24’s $28.2M.” Recent CEO departure and ER comments about flattish revenues are why it’s been hammered but long term I like it.
Hmm what’s the thesis on GERN if you don’t mind me asking?
I’m long LNTH CPRX and GERN.
Nice gain on FGEN, congrats! GERN is longer term for me, like 3-4 months when I expect to make a decision on whether I will hold or try to finance them with other options so I don't suffer the decay.
I own a few $2 calls for Jan 2026 for GERN, not sure about the other 2.
Its my tactic too. What do you think about FGEN GERN and PSTV?
Just like yesterday, I am still in ASM and GERN, but I've put myself into IPA and MCRB as they just got some good news.
I'm in ASM and GERN today, then maybe CMTL depending on how earnings go AH.
Ok I changed my mind, fuck GERN.
Lets go TKO and GERN, give me then green candles after earnings
Only two out of the four companies you mentioned actually have FDA-approved drugs: Geron (GERN) and SCYNEXIS (SCYX). Geron's Rytelo (imetelstat) is approved for low to intermediate risk MDS, a condition that affects a relatively small patient population (around 60,000 - 100,000 people in the U.S.). While there is some demand, it’s not exactly a blockbuster drug, and there are several other alternatives. SCYNEXIS’s Brexafemme (ibrexafungerp) was approved for treating vaginal yeast infections, but sales were halted due to manufacturing issues after the company found potential cross-contamination risks. GSK, which now handles its commercialization, is working on a solution, but the drug is currently off the market. So, if your argument is based solely on FDA approvals, it’s not as strong as you think. Having an FDA-approved drug doesn’t automatically make a stock a better investment - especially when one isn’t a major market mover and the other isn’t even being sold right now.
Look into ITRM, GERN, ATOS, SCYX. Much closer to making you money on being a bag holder.
I think it’s too early to play this. You need to find a play not on the brink of delisting or RS to stay listed. I looked over this myself but think GERN, ITMR, ATOS are better picks. I have made the mistake of rolling profits into the garbage. If you want your money to be doing something for you while you wait, put it into something safe. Or hold for that next big play.
GERN - Nobel prize winning drug
Anyone else here into good biopharms? I have positions in LNTH, GERN (finally has a successful drug on the market after 20 years), and CPRX.
Adding here my new game for the next week: GERN Huge potential for flying up on the financial results that will be provided soon. Analytics are very bullish with the target price of 8.2$ (2.9$ now).
I bought 23k shares with what i had in GERN(since it bounced around for a few months). YOLO!
I’ve been long GERN for years. Hoping with the institutional investment and likely expansion to the EU this stock will get to where it deserves. Their income stream is expanding rapidly too.
I’ve been invested in $GERN for a long time. Just got FDA approval and initiated sales in 3rd QTR that beat estimates. However, still has little stock price appreciation. 85% owned by institutions.
GERN please. Happy Thanksgiving
# **TLDR** --- **Ticker:** GERN **Direction:** Up **Prognosis:** Buy (YOLO) **Institutional Ownership:** 95% **Short Squeeze Potential:** High - 70M shares shorted, only 30M available for retail. Needs a few whales to ignite.
u/ComfyRug heres a few for you if you don't mind GERN, LUCD, PRSO, AEMD, MU, LODE
MDGL and GERN (not investment advice)
Fair, I'm going to look up my favorite long suffering biotech $GERN. Thanks!
GERN. Their first quarter of real earnings since the company’s founding will be revealed in their upcoming earnings in a few weeks.
$GERN I've been in and out for over 10 years and it's the only thing I think I have a reasonable understanding of in the market so when approval of their drug became likely and ultimately came to pass I went all in.
i got a free stock in 2020 for GERN at 1.20. I should’ve just full ported the 2,000 i had and left it alone
Id be weary of any biotech company. It’s a hope and a prayer with them. Believe me, got burned on ticker GERN years ago.
I am going to take a look at that one, thanks! I'm currently going whole hog on GERN, they have a recently approved telomerase inhibitor that provides statistically significant transfusion independence for a subset of the MDS patient group. Has potential as a combo therapy in a wide range of other cancers but that has yet to be born out by trials. I'd be interested to hear your thoughts on their prospects.
Reality: GERN has a market cap of $2.3 billion. Reality: The volume for GERN on the day of the BanBet was 19.5 million. u/Miserable-Welcome-87 : >Make bet on super illiquid micro cap and walk the price down yourself for a few hundo Sure... ok. Why let reality and facts get in the way of your misguided opinion? Have a great day.
GERN - the stock broke out of a two decade long base and just got their drug approved last month.
Still sitting on $GERN? I have (IMO) a lot of shares. I feel like it should be worth so much more once they start commercialization. What are your thoughts? The price has cooled down a lot since the FDA announcement
What do yall think about GERN?? I really like it myself
GERN, but that ship has mostly sailed away for folks not in.
Especially last year I did a lot of DD on penny stock, GERN VERU TERN ALT and many more, all of them did very well. When I started chasing, I started to loose. See my posts, last months dogsh** before that...nearly all successful waiting games
Apple Tesla BDTX GERN Affirm 🤷♂️
AEMD, GME FIFE, BRTX, BARK, HOLO,GERN have been my play the last month oh and GNDR now.
$GERN will run again. Load up lads and ladies.
What do you think about adding to a GERN position right now?
Sold too early on $GERN and $HUMA - still made a decent profit on each. $ANVS - tomorrow conference meeting, hopefully an update on their Buntanetap trial for Parkinson Disease. Readout should be within this month. Saw a job posting for a Senior Clinical Scientist posted two days ago. Looking extremely bullish. Hopefully tomorrow we can see a big green candle AH to push us back to the $12 and $13
$GERN, already pumped but go ahead and buy calls please
Thanks for the GERN tip a few days ago. Buy is up a very healthy 32% in a week or so. Not sure how long I’ll hold it for but for now it’s good. :)
GERN short squeeze tomorrow...drug approved tonight
GERN short squeeze tomorrow...drug approved tonight
I'm gonna need you guys to rotate back into biotech and start pumping $GERN for me into its PDUFA date in June.
$ANVS - Misguided trial saw the stock tank 70% but it is recovering very nicely - new data to be released in June. $HOLO - Hoping to rinse the shorts (I bought warrants), hoping for that skyrocket $GERN - PDUFA next month $ADAP - PDUFA upcoming $CTXR - within next 45 days Mino-Lok data will be released also has a PDUFA for another drug later this year
GERN is my largest holding. Mainly because of their blood cancer drug Imetelstat
$ADAP $GERN $CTXR all down, been a rough week. I don’t got any more ammo to add. Guessing biostocks taking a huge hit today